Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 23 entries
Sorted by: Best Match Show Resources per page
Sphingosine Kinases/Sphingosine 1-Phosphate Signaling in Hepatic Lipid Metabolism.

Current pharmacology reports

Kwong EK, Li X, Hylemon PB, Zhou H.
PMID: 29130028
Curr Pharmacol Rep. 2017 Aug;3:176-183. doi: 10.1007/s40495-017-0093-2. Epub 2017 Jun 20.

The ever-increasing prevalence of metabolic diseases such as dyslipidemia and diabetes in the western world continues to be of great public health concern. Biologically active sphingolipids, such as sphingosine 1-phosphate (S1P) and ceramide, are important regulators of lipid metabolism....

Cite
Kwong EK, Li X, Hylemon PB, et al. Sphingosine Kinases/Sphingosine 1-Phosphate Signaling in Hepatic Lipid Metabolism. Curr Pharmacol Rep. 2017;3:176-183doi: 10.1007/s40495-017-0093-2.
Kwong, E. K., Li, X., Hylemon, P. B., & Zhou, H. (2017). Sphingosine Kinases/Sphingosine 1-Phosphate Signaling in Hepatic Lipid Metabolism. Current pharmacology reports, 3176-183. https://doi.org/10.1007/s40495-017-0093-2
Kwong, Eric K, et al. "Sphingosine Kinases/Sphingosine 1-Phosphate Signaling in Hepatic Lipid Metabolism." Current pharmacology reports vol. 3 (2017): 176-183. doi: https://doi.org/10.1007/s40495-017-0093-2
Kwong EK, Li X, Hylemon PB, Zhou H. Sphingosine Kinases/Sphingosine 1-Phosphate Signaling in Hepatic Lipid Metabolism. Curr Pharmacol Rep. 2017 Aug;3:176-183. doi: 10.1007/s40495-017-0093-2. Epub 2017 Jun 20. PMID: 29130028; PMCID: PMC5678993.
Copy Download .nbib Format: NLM
Long Noncoding RNA H19: A Key Player in Liver Diseases.

Hepatology (Baltimore, Md.)

Wang Y, Hylemon PB, Zhou H.
PMID: 33630308
Hepatology. 2021 Sep;74(3):1652-1659. doi: 10.1002/hep.31765. Epub 2021 Aug 30.

No abstract available.

Cite
Wang Y, Hylemon PB, Zhou H. Long Noncoding RNA H19: A Key Player in Liver Diseases. Hepatology. 2021;74(3):1652-1659doi: 10.1002/hep.31765.
Wang, Y., Hylemon, P. B., & Zhou, H. (2021). Long Noncoding RNA H19: A Key Player in Liver Diseases. Hepatology (Baltimore, Md.), 74(3), 1652-1659. https://doi.org/10.1002/hep.31765
Wang, Yanyan, et al. "Long Noncoding RNA H19: A Key Player in Liver Diseases." Hepatology (Baltimore, Md.) vol. 74,3 (2021): 1652-1659. doi: https://doi.org/10.1002/hep.31765
Wang Y, Hylemon PB, Zhou H. Long Noncoding RNA H19: A Key Player in Liver Diseases. Hepatology. 2021 Sep;74(3):1652-1659. doi: 10.1002/hep.31765. Epub 2021 Aug 30. PMID: 33630308.
Copy Download .nbib Format: NLM
Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy.

Gut

Bajaj JS, Sikaroodi M, Shamsaddini A, Henseler Z, Santiago-Rodriguez T, Acharya C, Fagan A, Hylemon PB, Fuchs M, Gavis E, Ward T, Knights D, Gillevet PM.
PMID: 32998876
Gut. 2021 Jun;70(6):1162-1173. doi: 10.1136/gutjnl-2020-322470. Epub 2020 Sep 30.

OBJECTIVE: Altered bacterial composition is associated with disease progression in cirrhosis but the role of virome, especially phages, is unclear.DESIGN: Cross-sectional and pre/post rifaximin cohorts were enrolled. Cross-sectional: controls and cirrhotic outpatients (compensated, on lactulose (Cirr-L), on rifaximin (Cirr-LR))...

Cite
Bajaj JS, Sikaroodi M, Shamsaddini A, et al. Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy. Gut. 2020;70(6):1162-1173doi: 10.1136/gutjnl-2020-322470.
Bajaj, J. S., Sikaroodi, M., Shamsaddini, A., Henseler, Z., Santiago-Rodriguez, T., Acharya, C., Fagan, A., Hylemon, P. B., Fuchs, M., Gavis, E., Ward, T., Knights, D., & Gillevet, P. M. (2021). Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy. Gut, 70(6), 1162-1173. https://doi.org/10.1136/gutjnl-2020-322470
Bajaj, Jasmohan S, et al. "Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy." Gut vol. 70,6 (2021): 1162-1173. doi: https://doi.org/10.1136/gutjnl-2020-322470
Bajaj JS, Sikaroodi M, Shamsaddini A, Henseler Z, Santiago-Rodriguez T, Acharya C, Fagan A, Hylemon PB, Fuchs M, Gavis E, Ward T, Knights D, Gillevet PM. Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy. Gut. 2021 Jun;70(6):1162-1173. doi: 10.1136/gutjnl-2020-322470. Epub 2020 Sep 30. PMID: 32998876.
Copy Download .nbib Format: NLM
Bile acids as global regulators of hepatic nutrient metabolism.

Liver research

Hylemon PB, Takabe K, Dozmorov M, Nagahashi M, Zhou H.
PMID: 29123941
Liver Res. 2017 Jun;1(1):10-16. doi: 10.1016/j.livres.2017.03.002. Epub 2017 Apr 26.

Bile acids (BA) are synthesized from cholesterol in the liver. They are essential for promotion of the absorption of lipids, cholesterol, and lipid-soluble vitamins from the intestines. BAs are hormones that regulate nutrient metabolism by activating nuclear receptors (farnesoid...

Cite
Hylemon PB, Takabe K, Dozmorov M, et al. Bile acids as global regulators of hepatic nutrient metabolism. Liver Res. 2017;1(1):10-16doi: 10.1016/j.livres.2017.03.002.
Hylemon, P. B., Takabe, K., Dozmorov, M., Nagahashi, M., & Zhou, H. (2017). Bile acids as global regulators of hepatic nutrient metabolism. Liver research, 1(1), 10-16. https://doi.org/10.1016/j.livres.2017.03.002
Hylemon, Phillip B, et al. "Bile acids as global regulators of hepatic nutrient metabolism." Liver research vol. 1,1 (2017): 10-16. doi: https://doi.org/10.1016/j.livres.2017.03.002
Hylemon PB, Takabe K, Dozmorov M, Nagahashi M, Zhou H. Bile acids as global regulators of hepatic nutrient metabolism. Liver Res. 2017 Jun;1(1):10-16. doi: 10.1016/j.livres.2017.03.002. Epub 2017 Apr 26. PMID: 29123941; PMCID: PMC5673281.
Copy Download .nbib Format: NLM
Long Noncoding RNA H19: A Key Player in Liver Diseases.

Hepatology (Baltimore, Md.)

Wang Y, Hylemon PB, Zhou H.
PMID: 33630308
Hepatology. 2021 Sep;74(3):1652-1659. doi: 10.1002/hep.31765. Epub 2021 Aug 30.

No abstract available.

Cite
Wang Y, Hylemon PB, Zhou H. Long Noncoding RNA H19: A Key Player in Liver Diseases. Hepatology. 2021;74(3):1652-1659doi: 10.1002/hep.31765.
Wang, Y., Hylemon, P. B., & Zhou, H. (2021). Long Noncoding RNA H19: A Key Player in Liver Diseases. Hepatology (Baltimore, Md.), 74(3), 1652-1659. https://doi.org/10.1002/hep.31765
Wang, Yanyan, et al. "Long Noncoding RNA H19: A Key Player in Liver Diseases." Hepatology (Baltimore, Md.) vol. 74,3 (2021): 1652-1659. doi: https://doi.org/10.1002/hep.31765
Wang Y, Hylemon PB, Zhou H. Long Noncoding RNA H19: A Key Player in Liver Diseases. Hepatology. 2021 Sep;74(3):1652-1659. doi: 10.1002/hep.31765. Epub 2021 Aug 30. PMID: 33630308.
Copy Download .nbib Format: NLM
Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy.

Gut

Bajaj JS, Sikaroodi M, Shamsaddini A, Henseler Z, Santiago-Rodriguez T, Acharya C, Fagan A, Hylemon PB, Fuchs M, Gavis E, Ward T, Knights D, Gillevet PM.
PMID: 32998876
Gut. 2021 Jun;70(6):1162-1173. doi: 10.1136/gutjnl-2020-322470. Epub 2020 Sep 30.

OBJECTIVE: Altered bacterial composition is associated with disease progression in cirrhosis but the role of virome, especially phages, is unclear.DESIGN: Cross-sectional and pre/post rifaximin cohorts were enrolled. Cross-sectional: controls and cirrhotic outpatients (compensated, on lactulose (Cirr-L), on rifaximin (Cirr-LR))...

Cite
Bajaj JS, Sikaroodi M, Shamsaddini A, et al. Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy. Gut. 2020;70(6):1162-1173doi: 10.1136/gutjnl-2020-322470.
Bajaj, J. S., Sikaroodi, M., Shamsaddini, A., Henseler, Z., Santiago-Rodriguez, T., Acharya, C., Fagan, A., Hylemon, P. B., Fuchs, M., Gavis, E., Ward, T., Knights, D., & Gillevet, P. M. (2021). Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy. Gut, 70(6), 1162-1173. https://doi.org/10.1136/gutjnl-2020-322470
Bajaj, Jasmohan S, et al. "Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy." Gut vol. 70,6 (2021): 1162-1173. doi: https://doi.org/10.1136/gutjnl-2020-322470
Bajaj JS, Sikaroodi M, Shamsaddini A, Henseler Z, Santiago-Rodriguez T, Acharya C, Fagan A, Hylemon PB, Fuchs M, Gavis E, Ward T, Knights D, Gillevet PM. Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy. Gut. 2021 Jun;70(6):1162-1173. doi: 10.1136/gutjnl-2020-322470. Epub 2020 Sep 30. PMID: 32998876.
Copy Download .nbib Format: NLM
Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota Composition.

Clinical and translational gastroenterology

Kang DJ, Kakiyama G, Betrapally NS, Herzog J, Nittono H, Hylemon PB, Zhou H, Carroll I, Yang J, Gillevet PM, Jiao C, Takei H, Pandak WM, Iida T, Heuman DM, Fan S, Fiehn O, Kurosawa T, Sikaroodi M, Sartor RB, Bajaj JS.
PMID: 27560928
Clin Transl Gastroenterol. 2016 Aug 25;7(8):e187. doi: 10.1038/ctg.2016.44.

OBJECTIVES: Rifaximin has clinical benefits in minimal hepatic encephalopathy (MHE) but the mechanism of action is unclear. The antibiotic-dependent and -independent effects of rifaximin need to be elucidated in the setting of MHE-associated microbiota. To assess the action of...

Cite
Kang DJ, Kakiyama G, Betrapally NS, et al. Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota Composition. Clin Transl Gastroenterol. 2016;7(8):e187doi: 10.1038/ctg.2016.44.
Kang, D. J., Kakiyama, G., Betrapally, N. S., Herzog, J., Nittono, H., Hylemon, P. B., Zhou, H., Carroll, I., Yang, J., Gillevet, P. M., Jiao, C., Takei, H., Pandak, W. M., Iida, T., Heuman, D. M., Fan, S., Fiehn, O., Kurosawa, T., Sikaroodi, M., Sartor, R. B., & Bajaj, J. S. (2016). Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota Composition. Clinical and translational gastroenterology, 7(8), e187. https://doi.org/10.1038/ctg.2016.44
Kang, Dae J, et al. "Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota Composition." Clinical and translational gastroenterology vol. 7,8 (2016): e187. doi: https://doi.org/10.1038/ctg.2016.44
Kang DJ, Kakiyama G, Betrapally NS, Herzog J, Nittono H, Hylemon PB, Zhou H, Carroll I, Yang J, Gillevet PM, Jiao C, Takei H, Pandak WM, Iida T, Heuman DM, Fan S, Fiehn O, Kurosawa T, Sikaroodi M, Sartor RB, Bajaj JS. Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota Composition. Clin Transl Gastroenterol. 2016 Aug 25;7(8):e187. doi: 10.1038/ctg.2016.44. PMID: 27560928; PMCID: PMC5543406.
Copy Download .nbib Format: NLM
25-Hydroxycholesterol 3-sulfate is an endogenous ligand of DNA methyltransferases in hepatocytes.

Journal of lipid research

Wang Y, Lin W, Brown JE, Chen L, Pandak WM, Hylemon PB, Ren S.
PMID: 33705741
J Lipid Res. 2021;62:100063. doi: 10.1016/j.jlr.2021.100063. Epub 2021 Mar 08.

The oxysterol sulfate, 25-hydroxycholesterol 3-sulfate (25HC3S), has been shown to play an important role in lipid metabolism, inflammatory response, and cell survival. However, the mechanism(s) of its function in global regulation is unknown. The current study investigates the molecular...

Cite
Wang Y, Lin W, Brown JE, et al. 25-Hydroxycholesterol 3-sulfate is an endogenous ligand of DNA methyltransferases in hepatocytes. J Lipid Res. 2021;62:100063doi: 10.1016/j.jlr.2021.100063.
Wang, Y., Lin, W., Brown, J. E., Chen, L., Pandak, W. M., Hylemon, P. B., & Ren, S. (2021). 25-Hydroxycholesterol 3-sulfate is an endogenous ligand of DNA methyltransferases in hepatocytes. Journal of lipid research, 62100063. https://doi.org/10.1016/j.jlr.2021.100063
Wang, Yaping, et al. "25-Hydroxycholesterol 3-sulfate is an endogenous ligand of DNA methyltransferases in hepatocytes." Journal of lipid research vol. 62 (2021): 100063. doi: https://doi.org/10.1016/j.jlr.2021.100063
Wang Y, Lin W, Brown JE, Chen L, Pandak WM, Hylemon PB, Ren S. 25-Hydroxycholesterol 3-sulfate is an endogenous ligand of DNA methyltransferases in hepatocytes. J Lipid Res. 2021;62:100063. doi: 10.1016/j.jlr.2021.100063. Epub 2021 Mar 08. PMID: 33705741; PMCID: PMC8058565.
Copy Download .nbib Format: NLM
Hepatic Branch Vagotomy Modulates the Gut-Liver-Brain Axis in Murine Cirrhosis.

Frontiers in physiology

Zhang Y, Kang JD, Zhao D, Ghosh SS, Wang Y, Tai Y, Gonzalez-Maeso J, Sikaroodi M, Gillevet PM, Lippman HR, Hylemon PB, Zhou H, Bajaj JS.
PMID: 34248683
Front Physiol. 2021 Jun 25;12:702646. doi: 10.3389/fphys.2021.702646. eCollection 2021.

CONCLUSIONS: Hepatic vagal innervation affects the gut microbial composition, hepatic inflammation and steatosis, and cortical inflammation and BDNF expression and could be a critical modulator of the gut-liver-brain axis with consequences for HE development.

Cite
Zhang Y, Kang JD, Zhao D, et al. Hepatic Branch Vagotomy Modulates the Gut-Liver-Brain Axis in Murine Cirrhosis. Front Physiol. 2021;12:702646doi: 10.3389/fphys.2021.702646.
Zhang, Y., Kang, J. D., Zhao, D., Ghosh, S. S., Wang, Y., Tai, Y., Gonzalez-Maeso, J., Sikaroodi, M., Gillevet, P. M., Lippman, H. R., Hylemon, P. B., Zhou, H., & Bajaj, J. S. (2021). Hepatic Branch Vagotomy Modulates the Gut-Liver-Brain Axis in Murine Cirrhosis. Frontiers in physiology, 12702646. https://doi.org/10.3389/fphys.2021.702646
Zhang, Yuan, et al. "Hepatic Branch Vagotomy Modulates the Gut-Liver-Brain Axis in Murine Cirrhosis." Frontiers in physiology vol. 12 (2021): 702646. doi: https://doi.org/10.3389/fphys.2021.702646
Zhang Y, Kang JD, Zhao D, Ghosh SS, Wang Y, Tai Y, Gonzalez-Maeso J, Sikaroodi M, Gillevet PM, Lippman HR, Hylemon PB, Zhou H, Bajaj JS. Hepatic Branch Vagotomy Modulates the Gut-Liver-Brain Axis in Murine Cirrhosis. Front Physiol. 2021 Jun 25;12:702646. doi: 10.3389/fphys.2021.702646. eCollection 2021. PMID: 34248683; PMCID: PMC8268007.
Copy Download .nbib Format: NLM
Activation of Sirt1/FXR Signaling Pathway Attenuates Triptolide-Induced Hepatotoxicity in Rats.

Frontiers in pharmacology

Yang J, Sun L, Wang L, Hassan HM, Wang X, Hylemon PB, Wang T, Zhou H, Zhang L, Jiang Z.
PMID: 28536529
Front Pharmacol. 2017 May 09;8:260. doi: 10.3389/fphar.2017.00260. eCollection 2017.

Triptolide (TP), a diterpenoid isolated from

Cite
Yang J, Sun L, Wang L, et al. Activation of Sirt1/FXR Signaling Pathway Attenuates Triptolide-Induced Hepatotoxicity in Rats. Front Pharmacol. 2017;8:260doi: 10.3389/fphar.2017.00260.
Yang, J., Sun, L., Wang, L., Hassan, H. M., Wang, X., Hylemon, P. B., Wang, T., Zhou, H., Zhang, L., & Jiang, Z. (2017). Activation of Sirt1/FXR Signaling Pathway Attenuates Triptolide-Induced Hepatotoxicity in Rats. Frontiers in pharmacology, 8260. https://doi.org/10.3389/fphar.2017.00260
Yang, Jing, et al. "Activation of Sirt1/FXR Signaling Pathway Attenuates Triptolide-Induced Hepatotoxicity in Rats." Frontiers in pharmacology vol. 8 (2017): 260. doi: https://doi.org/10.3389/fphar.2017.00260
Yang J, Sun L, Wang L, Hassan HM, Wang X, Hylemon PB, Wang T, Zhou H, Zhang L, Jiang Z. Activation of Sirt1/FXR Signaling Pathway Attenuates Triptolide-Induced Hepatotoxicity in Rats. Front Pharmacol. 2017 May 09;8:260. doi: 10.3389/fphar.2017.00260. eCollection 2017. PMID: 28536529; PMCID: PMC5422577.
Copy Download .nbib Format: NLM
Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism.

Acta pharmaceutica Sinica. B

Kwong E, Li Y, Hylemon PB, Zhou H.
PMID: 26579441
Acta Pharm Sin B. 2015 Mar;5(2):151-7. doi: 10.1016/j.apsb.2014.12.009. Epub 2015 Feb 09.

The liver is the central organ involved in lipid metabolism. Dyslipidemia and its related disorders, including non-alcoholic fatty liver disease (NAFLD), obesity and other metabolic diseases, are of increasing public health concern due to their increasing prevalence in the...

Cite
Kwong E, Li Y, Hylemon PB, et al. Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism. Acta Pharm Sin B. 2015;5(2):151-7doi: 10.1016/j.apsb.2014.12.009.
Kwong, E., Li, Y., Hylemon, P. B., & Zhou, H. (2015). Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism. Acta pharmaceutica Sinica. B, 5(2), 151-7. https://doi.org/10.1016/j.apsb.2014.12.009
Kwong, Eric, et al. "Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism." Acta pharmaceutica Sinica. B vol. 5,2 (2015): 151-7. doi: https://doi.org/10.1016/j.apsb.2014.12.009
Kwong E, Li Y, Hylemon PB, Zhou H. Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism. Acta Pharm Sin B. 2015 Mar;5(2):151-7. doi: 10.1016/j.apsb.2014.12.009. Epub 2015 Feb 09. PMID: 26579441; PMCID: PMC4629213.
Copy Download .nbib Format: NLM
High Glucose Induces Lipid Accumulation via 25-Hydroxycholesterol DNA-CpG Methylation.

iScience

Wang Y, Chen L, Pandak WM, Heuman D, Hylemon PB, Ren S.
PMID: 32408171
iScience. 2020 May 22;23(5):101102. doi: 10.1016/j.isci.2020.101102. Epub 2020 Apr 29.

This work investigates the relationship between high-glucose (HG) culture, CpG methylation of genes involved in cell signaling pathways, and the regulation of carbohydrate and lipid metabolism in hepatocytes. The results indicate that HG leads to an increase in nuclear...

Cite
Wang Y, Chen L, Pandak WM, et al. High Glucose Induces Lipid Accumulation via 25-Hydroxycholesterol DNA-CpG Methylation. iScience. 2020;23(5):101102doi: 10.1016/j.isci.2020.101102.
Wang, Y., Chen, L., Pandak, W. M., Heuman, D., Hylemon, P. B., & Ren, S. (2020). High Glucose Induces Lipid Accumulation via 25-Hydroxycholesterol DNA-CpG Methylation. iScience, 23(5), 101102. https://doi.org/10.1016/j.isci.2020.101102
Wang, Yaping, et al. "High Glucose Induces Lipid Accumulation via 25-Hydroxycholesterol DNA-CpG Methylation." iScience vol. 23,5 (2020): 101102. doi: https://doi.org/10.1016/j.isci.2020.101102
Wang Y, Chen L, Pandak WM, Heuman D, Hylemon PB, Ren S. High Glucose Induces Lipid Accumulation via 25-Hydroxycholesterol DNA-CpG Methylation. iScience. 2020 May 22;23(5):101102. doi: 10.1016/j.isci.2020.101102. Epub 2020 Apr 29. PMID: 32408171; PMCID: PMC7225732.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 23 entries